On June 13, 2019, Amgen and
Allergan plc announced the
U.S. Food and Drug Administration (
FDA) has approved Kanjinti
™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin
® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Read corporate press release.
Posted 6/14/2019